Commodore Capital LP: SPYRE THERAPEUTICS INC (SYRE): Quarterly 13F Position History
As of Q1 2026, Commodore Capital LP reported 1,912,380 shares of SPYRE THERAPEUTICS INC (SYRE), worth $96.5M and representing 5.6% of its 13F equity book. Quarter-over-quarter share count change: 475,865 (-19.9%) . The position first appeared in Q3 2023 and has been disclosed across 11 13F-HR filings in Pactolio's tracked window.
- 1,912,380Shares Held (Latest Filing)
- $96.5MReported Market Value (Latest Filing)
- 5.6%Portfolio Weight (% of 13F Equity Book)
- 475,865Quarter-over-Quarter Share Change
- +$18.2MQuarter-over-Quarter Value Change
- 2,388,245Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 11 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 1,912,380 | 475,865 | -19.9% | $96.5M | 5.6% | $50.4 |
| Q4 2025 | 2,388,245 | +400,161 | +20.1% | $78.2M | 5.2% | $32.8 |
| Q3 2025 | 1,988,084 | 0 | — | $33.3M | 1.6% | $16.8 |
| Q2 2025 | 1,988,084 | 0 | — | $29.8M | 2.1% | $15.0 |
| Q1 2025 | 1,988,084 | 0 | — | $32.1M | 2.4% | $16.1 |
| Q4 2024 | 1,988,084 | 0 | — | $46.3M | 3.4% | $23.3 |
| Q3 2024 | 1,988,084 | 0 | — | $58.5M | 3.7% | $29.4 |
| Q2 2024 | 1,988,084 | +104,000 | +5.5% | $46.7M | 3.2% | $23.5 |
| Q1 2024 | 1,884,084 | 0 | — | $71.5M | 4.8% | $37.9 |
| Q4 2023 | 1,884,084 | +1,767,760 | +1519.7% | $40.5M | 3.5% | $21.5 |
| Q3 2023 | 116,324 | — | — | $1.4M | 0.2% | $12.3 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Commodore Capital LP first disclose a SYRE position in 13F-HR filings?
Commodore Capital LP first reported SPYRE THERAPEUTICS INC (SYRE) on its 13F-HR filing for the period ending 2023-09-30 (Q3 2023). The position has appeared on 11 reported quarters within Pactolio's tracked window.
What was Commodore Capital LP's most recent quarter-over-quarter share-count change in SYRE?
Between Q4 2025 and Q1 2026, Commodore Capital LP reduced its SYRE position by 475,865 shares (-19.9%), leaving 1,912,380 shares at a market value of $96.5M.
Does the implied price-per-share represent Commodore Capital LP's cost basis in SYRE?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.